Israel’s Bonus BioGroup (see here previously) tested its MesenCure MSC treatment on 10 severely ill, high risk Covid-19 patients at Haifa’s Rambam hospital. All ten improved sufficiently to be discharged just one day after treatment. MesenCure now advances to Phase 2 trials.
https://www.israel21c.org/israeli-biotech-company-aces-phase-i-covid-cure-trial/